Saturday, June 22, 2024

FDA Approves Self-Collection Kit for HPV Testing, Advancing Cervical Cancer Screening Accessibility

Similar articles

Cervical cancer screening has taken a significant leap forward with BD (Becton, Dickinson and Company) receiving the Food and Drug Administration (FDA) approval for a self-collection kit designed to facilitate HPV testing (human papillomavirus). This innovative approval allows individuals to self-collect vaginal specimens in healthcare settings, such as retail pharmacies, when traditional cervical samples cannot be obtained. This move is poised to enhance accessibility to screening, potentially encouraging more people to get tested and thereby improving overall screening rates.

BD announced on Wednesday that the FDA has approved its kit for self-collection of specimens for HPV testing. This approval enables people to collect their samples in non-traditional settings, such as retail pharmacies and mobile clinics, expanding the options for where screening can occur. The company believes that this flexibility will significantly increase access to cervical cancer screening, especially for those who might find it challenging to visit a traditional healthcare setting.

Nearly all cases of cervical cancer are linked to HPV, making HPV screening a crucial component of cervical cancer prevention strategies. Public health officials have long recognized the importance of regular screening, and in 2021, approximately 72% of women aged 21 to 65 in the U.S. were current with their cervical cancer screenings. The goal is to increase this rate to over 84% by the end of the decade.

BD’s Self-Collection Kit for HPV Testing Addresses Screening Barriers and Gains Strong Support

BD’s HPV testing kit is designed to help achieve this goal by addressing common barriers to screening. Jeff Andrews, vice president of global medical affairs for diagnostic solutions at BD, noted that many patients are uncomfortable with the intimate nature of a pelvic exam. Additionally, some people live in areas without a local doctor or clinician trained to obtain a sample using a speculum. The self-collection option can help overcome these barriers, allowing more people to get screened.

BD, in collaboration with Harris Poll, conducted a survey to assess attitudes toward self-collection among women in the U.S., U.K., and Sweden. The survey, published in January, found that 56% of women in the U.S. would feel comfortable performing a self-collected vaginal test at home for cervical cancer screening. Furthermore, two-thirds of U.S. respondents expressed interest in at-home screening for HPV or cervical cancer.

Reasons cited for this preference include the comfort of being in one’s own home, the ability to administer the test independently, and the convenience of not having to schedule an appointment with a healthcare provider. The survey also revealed that younger women are more likely to be interested in self-collection across all surveyed geographies.

HPV Testing

FDA Approval of BD’s HPV Testing Kit Set to Transform Cervical Cancer Screening Globally

Several countries have already implemented self-collection for cervical cancer screening with positive results. In Denmark, Sweden, the Netherlands, Kenya, Australia, and New Zealand, individuals can collect their samples. Sweden, for instance, began mailing self-collection kits to homes during the COVID-19 pandemic. After distributing 330,000 HPV testing kits around the capital city, test coverage increased from 75% to 85% within one year.

The FDA’s approval of BD’s self-collection kit for HPV testing marks a pivotal advancement in cervical cancer screening. By providing a convenient, private, and accessible option for sample collection, this innovation has the potential to significantly increase screening rates and reduce the incidence of cervical cancer. BD’s initiative reflects a broader trend toward empowering patients and making healthcare more accessible through technology and innovative solutions.

You can follow our news on our Telegram and LinkedIn accounts.

As the use of self-collection kits becomes more widespread, it is expected to have a transformative impact on public health. Increased screening rates will lead to earlier detection of cervical cancer, better patient outcomes, and ultimately, a reduction in the prevalence of this preventable disease. BD’s ongoing efforts to develop and market user-friendly diagnostic tools underscore the company’s commitment to improving healthcare access and patient empowerment globally.


Resource: Becton, Dickinson and Company, May 17, 2024

Subscribe to our newsletter

To be updated with all the latest news, offers and special announcements.

Latest article